• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一个可追溯到公元前 1000 年的乌拉尔图人中发现了莱顿因子 V。

Factor V Leiden in an Urartian, dating back to 1000 BC.

机构信息

Institute of Biotechnology, Ankara University, Turkey.

出版信息

Clin Appl Thromb Hemost. 2010 Dec;16(6):679-83. doi: 10.1177/1076029609338045. Epub 2009 Jul 17.

DOI:10.1177/1076029609338045
PMID:19617246
Abstract

Factor V Leiden (FVL) is the most common monogenic disorder that causes activated protein C (APC) resistance, creating hyper-coagulation. The mutation shows an uneven geographic distribution, significantly high in European populations. The mutation is believed to have originated approximately 20 000 years ago probably from a geographic region close to Anatolia. This fact makes it noteworthy to search for the mutation in ancient populations that once lived in this area. One of these civilizations, Urartu was centered around Van Lake in Eastern Turkey. The archeological remains from the excavations of the region are dated back to 1000 BC. Teeth, taken from the excavations of Van Yoncatepe fortress, were taken into DNA analysis considering all the precautions for ancient DNA analysis. Multiplex STR (Short Tandem Repeats) analysis were performed both to determine the gender of the samples and to conclude that the samples are preserved from modern DNA contamination. After getting an 80% amplification success for amelogenin, a melting curve analysis using lightcycler was performed to determine the FVL genotype of each sample. Of the 60 samples, 1 gave a positive amplification result for FV gene and was found to be heterozygous. To date, the age of this mutation was estimated based on statistical calculations using haplotype frequencies; here for the first time, we report FVL in an ancient population of 3000 years.

摘要

因子 V 莱顿突变(FVL)是最常见的单基因疾病,可导致激活蛋白 C(APC)抵抗,从而引起血液过度凝结。该突变呈不均匀的地理分布,在欧洲人群中发生率较高。据信,该突变大约在 20000 年前起源于接近安纳托利亚的某个地理区域。这一事实使得在曾经生活在该地区的古代人群中寻找该突变变得非常重要。其中一个文明是位于土耳其东部凡湖附近的阿尔塔什。该地区的考古遗址可以追溯到公元前 1000 年。从凡·约纳切佩堡垒的挖掘中提取了牙齿,并考虑到所有古代 DNA 分析的注意事项,对其进行了 DNA 分析。进行了多重 STR(短串联重复)分析,不仅确定了样本的性别,还得出结论,这些样本没有受到现代 DNA 污染。在获得 amelogenin 80%的扩增成功率后,使用 Lightcycler 进行了熔解曲线分析,以确定每个样本的 FVL 基因型。在 60 个样本中,有 1 个 FV 基因呈阳性扩增结果,且为杂合子。迄今为止,该突变的年龄是基于使用单倍型频率进行的统计计算来估计的;在这里,我们首次在 3000 年前的古代人群中报告了 FVL。

相似文献

1
Factor V Leiden in an Urartian, dating back to 1000 BC.在一个可追溯到公元前 1000 年的乌拉尔图人中发现了莱顿因子 V。
Clin Appl Thromb Hemost. 2010 Dec;16(6):679-83. doi: 10.1177/1076029609338045. Epub 2009 Jul 17.
2
The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.土耳其爱琴海地区代尼兹利健康人群中因子V莱顿突变的频率,以及因子V莱顿与凝血酶原G20210A突变和亚甲基四氢叶酸还原酶C677T基因突变的共存情况。
Clin Appl Thromb Hemost. 2007 Apr;13(2):166-71. doi: 10.1177/1076029606298990.
3
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].[活化蛋白C抵抗与静脉血栓形成倾向:德国人群的分子遗传学患病率研究]
Dtsch Med Wochenschr. 1999 Jun 25;124(25-26):783-7. doi: 10.1055/s-2007-1024412.
4
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.凝血因子V的HR2单倍型:对凝血因子V水平、标准化活化蛋白C敏感率及静脉血栓形成风险的影响
Thromb Haemost. 2000 Apr;83(4):577-82.
5
Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.一项基于功能性凝血酶原时间检测法对一组意大利静脉血栓形成患者中因子V莱顿突变携带者进行鉴定的临床评估。
Blood Coagul Fibrinolysis. 2007 Oct;18(7):603-10. doi: 10.1097/MBC.0b013e3282891e2f.
6
Probability of recurrence of thrombosis in patients with and without factor V Leiden.有和没有凝血因子V莱顿突变的患者血栓形成复发的概率。
Thromb Haemost. 1996 Feb;75(2):229-32.
7
Factor V Leiden mutation in one family of Chinese origin.一个华裔家庭中的凝血因子V莱顿突变
Chin Med J (Engl). 2001 Apr;114(4):379-81.
8
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.活化蛋白C抵抗试验可检测除因子V莱顿突变以外的血栓形成危险因素。
Am J Clin Pathol. 2003 Jan;119(1):52-60. doi: 10.1309/QCUU-NRMV-JY8M-WPPL.
9
Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.一名血栓形成患者中 I 型定量因子 V 缺乏症的分子特征,该患者对活化蛋白 C 抵抗呈“假纯合子”状态。
Thromb Haemost. 1997 Feb;77(2):252-7.
10
The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.
Turk J Pediatr. 1997 Jul-Sep;39(3):313-5.

引用本文的文献

1
Spatio-temporal dynamics of pathogenic variants associated with monogenic disorders reconstructed with ancient DNA.利用古 DNA 重建与单基因疾病相关的致病变体的时空动态。
PLoS One. 2022 Jun 24;17(6):e0269628. doi: 10.1371/journal.pone.0269628. eCollection 2022.
2
The distribution of Factor V Leiden mutation.凝血因子V莱顿突变的分布情况。
J Thromb Thrombolysis. 2013 Oct;36(3):341-2. doi: 10.1007/s11239-012-0848-x.